Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 100 of 178 entries
View as:

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Phase: N/A Priority: Normal
NCT ID: NCT02795156 Org: User:
Start: 09/28/16 End: 08/17/22 Due: 08/17/23

Review of Molecular Profiling-Real Time Polymerase Chain Reaction (Rt-Pcr) in Unknown Primary Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00876408 Org: User:
Start: 05/31/09 End: 11/30/10 Due: 11/30/11

Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Refractory and/or Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00193583 Org: User:
Start: 05/31/03 End: 05/31/05 Due: 05/31/06

Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00297596 Org: User:
Start: 02/28/06 End: 10/31/10 Due: 10/31/11

Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01035658 Org: User:
Start: 01/31/10 End: 03/31/14 Due: 03/31/15

Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00193557 Org: User:
Start: 05/31/04 End: 01/31/09 Due: 01/31/10

A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)

Phase: N/A Priority: Normal
NCT ID: NCT04200365 Org: User:
Start: 06/05/20 End: 09/07/23 Due: 09/07/24

Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

Phase: N/A Priority: Normal
NCT ID: NCT00536341 Org: User:
Start: 01/31/08 End: 11/30/16 Due: 11/30/17

LBH589 in Refractory Myelodysplastic Syndromes (MDS)

Phase: N/A Priority: Normal
NCT ID: NCT00594230 Org: User:
Start: 01/31/08 End: 03/31/11 Due: 03/31/12

Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00876382 Org: User:
Start: 05/31/09 End: 08/31/11 Due: 08/31/12

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT01871675 Org: User:
Start: 05/31/13 End: 06/30/16 Due: 06/30/17

5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00308516 Org: User:
Start: 03/31/06 End: 02/29/12 Due: 02/28/13

Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00866905 Org: User:
Start: 04/30/09 End: 10/31/14 Due: 10/31/15

Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00193375 Org: User:
Start: 08/31/03 End: 05/31/08 Due: 05/31/09

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)

Phase: N/A Priority: Normal
NCT ID: NCT07011576 Org: User:
Start: 07/31/25 End: 06/30/27 Due: 06/30/28

Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02113007 Org: User:
Start: 07/31/14 End: 02/29/16 Due: 02/28/17

5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01749956 Org: User:
Start: 01/31/13 End: 09/30/15 Due: 09/30/16

Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00193297 Org: User:
Start: 02/28/02 End: 06/30/06 Due: 06/30/07

Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00193284 Org: User:
Start: 10/31/03 End: 01/31/09 Due: 01/31/10

PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00759928 Org: User:
Start: 10/31/08 End: 06/30/14 Due: 06/30/15

Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00193232 Org: User:
Start: 05/31/04 End: 02/28/07 Due: 02/28/08

Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01048099 Org: User:
Start: 01/31/11 End: 07/31/14 Due: 07/31/15

Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00284154 Org: User:
Start: 01/31/06 End: 11/30/09 Due: 11/30/10

Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00915603 Org: User:
Start: 07/31/09 End: 07/31/14 Due: 07/31/15

Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib

Phase: N/A Priority: Normal
NCT ID: NCT05948462 Org: User:
Start: 11/30/23 End: 09/30/25 Due: 09/30/26